Samsca

Trials studying Samsca

• phase3A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)recruitingn=20
• phase3A Study to See if Tolvaptan Can Delay Dialysis in Infants and Children Who at Enrollment Are 28 Days to Less Than 12 Weeks Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)withdrawn
• —Post-Marketing Surveillance Study of Tolvaptan in Patients With ADPKDcompletedn=1,802
• phase1A Study of HRS-9057 in Patients With Heart Failure and Volume Overloadcompletedn=25
• phase1Phase I Study Multi Dose of 7.5mg Tolvaptan in Health Malecompletedn=12
• phase1Single Dose of 7.5mg Tolvaptan Phase I Clinical Trial Protocolcompletedn=10
• —Samsca PMS in ADPKD Patientscompletedn=2,067
• phase2A Phase 2 Efficacy and Safety Study of the Tolvaptan Tablets in Patients With Non-hypovolemic Non-acute Hyponatremiacompletedn=241